Start here if you're new
what it is
James River sells specialty insurance for small and mid-size business risks in the U.S.
how it gets paid
Last year James River made $688M in revenue. E&S casualty underwriting was the main engine at $450M, or 65% of sales.
why growth slowed
Revenue fell 2.8% last year. Revenue was the number that mattered because $520M showed the business was far above the prior-year base.
what just happened
$520M in revenue and $0.20 EPS reset the quarter.
At a glance
C+ balance sheet — struggling to keep the lights on
5/100 earnings predictability — expect surprises
8.3x trailing p/e — the market's not buying it — or you found a deal
0.6% dividend yield — cash in your pocket every quarter
4.7% return on capital — nothing to write home about
xvary composite: 44/100 — below average
What they do
James River sells specialty insurance for small and mid-size business risks in the U.S.
Gross written premiums → total policy dollars written → 76.2% came from E&S lines. Net written premiums → the dollars left after reinsurance → 88.7% also came from E&S lines. You are buying a specialist, not a generalist. That is a moat when E&S pricing is hot. It breaks if the E&S mix falls below 60%.
How they make money
$688M
annual revenue · their business grew -2.8% last year
E&S casualty underwriting
$450M
E&S property underwriting
$60M
Casualty reinsurance
$110M
Specialty admitted insurance
$45M
Run-off and other
$23M
The products that matter
specialty commercial insurance
Excess & Surplus Lines
$565M · 82.1% of revenue
this is the core book at $565M. if you buy JRVR, you are mostly buying the underwriting quality of this segment and whatever pricing discipline sits behind it.
core segment
specialty admitted underwriting
Specialty Admitted Insurance
$123M · 17.9% of revenue
the admitted business matters, but scale matters more. at $123M, it can help around the edges. it cannot cover for weak performance in the main book.
secondary book
legacy risk pocket
Commercial Auto
page data is thin
the missing detail matters. in insurance, older problem books can keep showing up in results long after the original policies were written. when the feed is thin, you should assume the legacy piece still deserves attention.
watch closely
Key numbers
76.2%
E&S mix
Gross premium dollars are heavily tied to one niche, so the company lives and dies by E&S pricing.
4.7%
Capital return
Every $100 tied up in the business earned $4.70 in profit.
$330M
Debt load
Long-term debt equals 53% of capital, so leverage is not a side note.
8.3x
Trailing P/E
You are paying 8.3 times trailing earnings, which is cheap only if profits hold.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 2 — safer than 80% of stocks
- price stability 20 / 100
- long-term debt $330M (53% of capital)
C+ — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for JRVR right now.
source: institutional data · return history unavailable
What just happened
beat estimates
$520M in revenue and $0.20 EPS reset the quarter.
Revenue rose 201% vs. prior year, and EPS rose 1,100% vs. prior year. The base was weak, so the rebound did a lot of the work.
$172M
revenue
$0.20
eps
+201%
revenue growth
the number that mattered
Revenue was the number that mattered because $520M showed the business was far above the prior-year base.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
JRVR does not need a dramatic external shock to disappoint you. The current numbers already show the main problem: a turnaround case built on 4.7% return on capital, one dominant segment, and a balance sheet that does not love mistakes.
med
underwriting improvement never shows up
the stock is being asked to bridge a return gap from 4.7% today to a mid-teen return on equity target through 2026. if that gap barely moves, the low valuation is not a setup. it is the right price for an insurer that has not fixed the core math.
if 2026 ends with returns still parked near 4.7%, the rerating case probably disappears with it.
med
the core segment stays flat
Excess & Surplus Lines produces $565M of revenue, or 82.1% of the total. concentration cuts both ways. it gives you a clean way to win, and one obvious place to fail.
if the main book does not improve, the $123M admitted segment is too small to rescue the story.
med
legacy loss issues keep leaking into results
commercial auto is a thin-data area on this page, which is exactly why it deserves attention. older insurance books have a habit of revisiting current earnings long after investors think the problem is over.
if reserve pain from legacy business lingers, clean quarter-to-quarter progress gets harder to prove.
med
systems work and debt leave little room for error
management has flagged a major systems implementation for 2026, while the company already carries a C+ balance sheet and $330M of long-term debt, or 53% of capital. that is a lot to juggle for a $294M market cap insurer.
even necessary internal work can delay margin repair, and the debt means the clock matters.
here's the thing: the kill criteria are not mysterious. if earnings keep missing and return on capital stays stuck near 4.7%, the turnaround thesis fails. if those numbers improve, the stock finally has room to act cheap.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Q1 2026 earnings
analysts expect $0.28 EPS on $172.31M of revenue in may 2026. after a 26% miss, the next print needs to look boring in the best possible way.
returns
the 4.7% return problem
management's target is a mid-teen return on equity through 2026. today's page shows 4.7% return on capital. that gap is the entire debate.
balance sheet
debt and flexibility
$330M of long-term debt equals 53% of capital. if earnings stay uneven, the balance sheet stops being background noise and becomes the story.
growth
revenue stabilization
revenue fell 2.8% to $688M, while the cited 2026 sales outlook is $697.9M. you are looking for stabilization first, then proof the return profile is following it higher.
Analyst rankings
earnings predictability
5 / 100
a 5 / 100 score means analysts have very little confidence in clean, repeatable earnings. in human-speak, this stock is likely to keep surprising people until management proves otherwise.
source: institutional data
Institutional activity
institutional ownership data for JRVR is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$6
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive